/PRNewswire/ Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and commercialize KHK4083, which is.
Amgen and Kyowa Kirin agree to jointly develop eczema med
1st June 2021
Amgen and Kyowa Kirin have signed an agreement to jointly develop and commercialise KHK4083, a monoclonal antibody (mAb) in development for the treatment of atopic dermatitis – the most common form of eczema.
As part of the agreement, Amgen will take the lead on the development, manufacturing and commercialisation of KHK4083 for all markets globally, excluding Japan where Kyowa Kirin will retain all rights.
Kyowa Kirin will also co-promote the mAb with Amgen in the US and have opt-in rights to co-promote KHK4083 in certain other markets, including Europe and Asia.
DUPIXENT® (dupilumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate-to-severe atopic dermatitis yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Tanker owners face many questions from navigating out of the current loss-making market, what fuels to use in the future for their vessels and climate change